Featured Publications
Real-Time Prediction of Acute Kidney Injury in Hospitalized Adults: Implementation and Proof of Concept
Ugwuowo U, Yamamoto Y, Arora T, Saran I, Partridge C, Biswas A, Martin M, Moledina DG, Greenberg JH, Simonov M, Mansour SG, Vela R, Testani JM, Rao V, Rentfro K, Obeid W, Parikh CR, Wilson FP. Real-Time Prediction of Acute Kidney Injury in Hospitalized Adults: Implementation and Proof of Concept. American Journal Of Kidney Diseases 2020, 76: 806-814.e1. PMID: 32505812, PMCID: PMC8667815, DOI: 10.1053/j.ajkd.2020.05.003.Peer-Reviewed Original ResearchConceptsAKI alertsHospitalized adultsKidney injuryUrban tertiary care hospitalAcute kidney injurySerum creatinine levelsObservational cohort studyTertiary care hospitalSerum creatinine concentrationBeats/minElectronic health recordsAKI diagnosisCohort studyCreatinine levelsInpatient mortalitySystolic bloodFractional excretionCenter studyBlood biomarkersUnivariable associationsUrine microscopyCreatinine concentrationClinical careElevated riskUrea nitrogen
2024
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2024, 134: e180583. PMID: 38488004, PMCID: PMC10940080, DOI: 10.1172/jci180583.Peer-Reviewed Original Research
2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatientsEvaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19
Menez S, Coca S, Moledina D, Wen Y, Chan L, Thiessen-Philbrook H, Obeid W, Garibaldi B, Azeloglu E, Ugwuowo U, Sperati C, Arend L, Rosenberg A, Kaushal M, Jain S, Wilson F, Parikh C, Consortium T, Deng J, Atta M, Bagnasco S, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19. American Journal Of Kidney Diseases 2023, 82: 322-332.e1. PMID: 37263570, PMCID: PMC10229201, DOI: 10.1053/j.ajkd.2023.03.010.Peer-Reviewed Original ResearchConceptsSoluble tumor necrosis factor receptor 1Major adverse kidney eventsAdverse kidney eventsAdverse kidney outcomesAcute kidney injuryKidney eventsTumor necrosis factor receptor 1Necrosis factor receptor 1Plasma biomarkersKidney outcomesC-indexFactor receptor 1Hospitalized patientsCOVID-19KDIGO stage 3 acute kidney injuryDialysis-requiring acute kidney injuryStage 3 acute kidney injuryLong-term adverse health outcomesReceptor 1Long-term kidney dysfunctionAvailable blood samplesIdentification of patientsProportional hazards regressionAdverse health outcomesCOVID-19 hospitalization
2022
Urine Uromodulin as a Biomarker of Kidney Tubulointerstitial Fibrosis
Melchinger H, Calderon-Gutierrez F, Obeid W, Xu L, Shaw MM, Luciano RL, Kuperman M, Moeckel GW, Kashgarian M, Wilson FP, Parikh CR, Moledina DG. Urine Uromodulin as a Biomarker of Kidney Tubulointerstitial Fibrosis. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1284-1292. PMID: 35948365, PMCID: PMC9625093, DOI: 10.2215/cjn.04360422.Peer-Reviewed Original ResearchMeSH KeywordsAlbuminsAnimalsAtrophyBiomarkersCreatinineFibrosisHumansKidneyKidney DiseasesMiceUromodulinConceptsInterstitial fibrosis/tubular atrophyUrine uromodulinTubular atrophyThick ascending limbUrine albuminSerum creatinineKidney biopsyTubulointerstitial fibrosisMultivariable linear regression modelsTime of biopsyKidney's thick ascending limbAcademic medical centerHuman kidney biopsiesKidney tubulointerstitial fibrosisTubular healthMultivariable analysisHistologic featuresHistologic findingsHistologic changesKidney fibrosisIndependent associationFibrotic modelMultivariable modelMedical CenterMurine modelAssociation of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study
Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS. Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Medicine 2022, 48: 1144-1155. PMID: 35833959, PMCID: PMC9463324, DOI: 10.1007/s00134-022-06811-0.Peer-Reviewed Original ResearchConceptsPiperacillin-tazobactamKidney biomarkersCystatin CAcute kidney injury riskProspective cohort studyCystatin C concentrationCystatin C measurementKidney function biomarkersCreatinine secretionAntibiotic initiationCohort studyProspective cohortIll adultsClinical outcomesAssociation of vancomycinAntibiotic treatmentTubular secretionCreatinine concentrationTreatment weightingResultsThe studyTrue injuryHigh incidenceCreatinineDay 14Early changesHemoconcentration of Creatinine Minimally Contributes to Changes in Creatinine during the Treatment of Decompensated Heart Failure
Maulion C, Chen S, Rao VS, Ivey-Miranda JB, Cox ZL, Mahoney D, Coca SG, Negoianu D, Asher JL, Turner JM, Inker LA, Wilson FP, Testani JM. Hemoconcentration of Creatinine Minimally Contributes to Changes in Creatinine during the Treatment of Decompensated Heart Failure. Kidney360 2022, 3: 1003-1010. PMID: 35845336, PMCID: PMC9255871, DOI: 10.34067/kid.0007582021.Peer-Reviewed Original ResearchClinically adjudicated deceased donor acute kidney injury and graft outcomes
Mansour SG, Khoury N, Kodali R, Virmani S, Reese PP, Hall IE, Jia Y, Yamamoto Y, Thiessen-Philbrook HR, Obeid W, Doshi MD, Akalin E, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Singh P, Weng FL, Moledina DG, Greenberg JH, Wilson FP, Parikh CR. Clinically adjudicated deceased donor acute kidney injury and graft outcomes. PLOS ONE 2022, 17: e0264329. PMID: 35239694, PMCID: PMC8893682, DOI: 10.1371/journal.pone.0264329.Peer-Reviewed Original ResearchConceptsDonor Acute Kidney InjuryAcute kidney injuryGraft failureAKI phenotypesKidney injuryUrine biomarkersLack of associationAKI casesGraft functionHigher DGFPotential kidneyGraft outcomeDeceased donorsOrgan utilizationMCP-1YKL-40Donor StudyEGFRDGFAncillary analysisAvailable chartsBiomarkersInjuryPhenotypeAssociation
2021
Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data
Moledina DG, Eadon MT, Calderon F, Yamamoto Y, Shaw M, Perazella MA, Simonov M, Luciano R, Schwantes-An TH, Moeckel G, Kashgarian M, Kuperman M, Obeid W, Cantley LG, Parikh CR, Wilson FP. Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrology Dialysis Transplantation 2021, 37: 2214-2222. PMID: 34865148, PMCID: PMC9755995, DOI: 10.1093/ndt/gfab346.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisInterstitial nephritisUrine biomarkersBiopsy-proven acute interstitial nephritisElectronic health record dataExternal validation cohortTypical clinical featuresBlood urea nitrogenTumor necrosis factorCharacteristic curve analysisHealth record dataExternal validationElectronic health recordsAIN diagnosisModest AUCsSerum creatinineCreatinine ratioKidney biopsyClinical featuresValidation cohortNecrosis factorUnrecognized casesInterleukin-9PatientsUrea nitrogenPrognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19
Menez S, Moledina DG, Thiessen-Philbrook H, Wilson FP, Obeid W, Simonov M, Yamamoto Y, Corona-Villalobos CP, Chang C, Garibaldi BT, Clarke W, Farhadian S, Dela Cruz C, Coca SG, Parikh CR, Investigators T, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19. American Journal Of Kidney Diseases 2021, 79: 257-267.e1. PMID: 34710516, PMCID: PMC8542781, DOI: 10.1053/j.ajkd.2021.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryBiomarkersCOVID-19CreatinineHumansLipocalin-2PrognosisProspective StudiesSARS-CoV-2ConceptsAdverse kidney outcomesNeutrophil gelatinase-associated lipocalinUrinary biomarkersBiomarker levelsKidney outcomesPrimary outcomeClinical AKIKidney injuryComposite outcomeCOVID-19KDIGO stage 3 AKIKidney injury molecule-1Cox proportional hazards regressionEpidermal growth factor levelsStage 3 AKIPrimary composite outcomeInjury molecule-1Kidney disease progressionGelatinase-associated lipocalinAdditional prognostic informationComposite outcome eventsProportional hazards regressionCOVID-19 patientsGrowth factor levelsCoronavirus disease 2019AACC Guidance Document on Laboratory Investigation of Acute Kidney Injury
El-Khoury JM, Hoenig MP, Jones GRD, Lamb EJ, Parikh CR, Tolan NV, Wilson FP. AACC Guidance Document on Laboratory Investigation of Acute Kidney Injury. The Journal Of Applied Laboratory Medicine 2021, 6: 1316-1337. PMID: 33973621, DOI: 10.1093/jalm/jfab020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute kidney injuryKidney injuryNew biomarkersPotential acute kidney injuryInsulin-like growth factor binding protein 7Growth factor binding protein 7Early detectionLong-term complicationsLaboratory investigationsEmergence of biomarkersHealth care costsBinding protein 7AKI alertsKidney damageClinical indicationsCystatin CSudden episodeCare costsTissue inhibitorDiagnostic thresholdMetalloproteinases 2Test utilizationPreponderance of evidenceTraditional markersExpert recommendationsA neutrophil activation signature predicts critical illness and mortality in COVID-19
Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances 2021, 5: 1164-1177. PMID: 33635335, PMCID: PMC7908851, DOI: 10.1182/bloodadvances.2020003568.Peer-Reviewed Original ResearchConceptsCritical illnessHealth system databaseNeutrophil activationCOVID-19Neutrophil activation signatureSevere COVID-19Intensive care unitGranulocyte colony-stimulating factorHigh mortality rateColony-stimulating factorSystem databaseHepatocyte growth factorClinical decompensationNeutrophil countImmune hyperactivationCare unitEarly elevationLipocalin-2Interleukin-8Longitudinal cohortClinical dataMortality ratePatientsIllnessActivation signatureNatriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure
Rao VS, Ivey-Miranda JB, Cox ZL, Riello R, Griffin M, Fleming J, Soucier R, Sangkachand P, O'Brien M, LoRusso F, D'Ambrosi J, Churchwell K, Mahoney D, Bellumkonda L, Asher JL, Maulion C, Turner JM, Wilson FP, Collins SP, Testani JM. Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure. Journal Of The American College Of Cardiology 2021, 77: 695-708. PMID: 33573739, PMCID: PMC8114781, DOI: 10.1016/j.jacc.2020.12.022.Peer-Reviewed Original ResearchConceptsLoop diuretic administrationDiuretic therapyNatriuretic responseDiuretic administrationSodium outputAcute decompensated heart failureDecompensated heart failureHeart failure admissionsDaily urine outputSpot urine samplesNet fluid outputNet fluid lossPathway cohortHeart failureLoop diureticsUrine outputDiuretic responseResidual congestionFluid outputTherapyCohortWeight lossAdditional studiesUrine samplesExcellent discrimination
2020
Results from the TRIBE-AKI Study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery
Menez S, Moledina DG, Garg AX, Thiessen-Philbrook H, McArthur E, Jia Y, Liu C, Obeid W, Mansour SG, Koyner JL, Shlipak MG, Wilson FP, Coca SG, Parikh CR. Results from the TRIBE-AKI Study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery. Kidney International 2020, 99: 716-724. PMID: 32721447, PMCID: PMC8077034, DOI: 10.1016/j.kint.2020.06.037.Peer-Reviewed Original ResearchConceptsEstimated glomerular filtration rateChronic kidney diseaseBaseline estimated glomerular filtration rateCardiac surgeryCKD incidenceKidney diseaseBlood biomarkersN-terminal pro-B-type natriuretic peptideDevelopment of CKDPro-B-type natriuretic peptideReplication cohortAcute kidney injury groupLong-term kidney outcomesKidney injury molecule-1Acute kidney injuryPrimary composite outcomeInjury molecule-1Post-operative levelsGlomerular filtration rateTumor necrosis factor receptor 1Necrosis factor receptor 1Basic fibroblast growth factorFactor receptor 1Fibroblast growth factorAKI studies
2019
Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure
Griffin M, Rao VS, Fleming J, Raghavendra P, Turner J, Mahoney D, Wettersten N, Maisel A, Ivey-Miranda JB, Inker L, Tang WHW, Wilson FP, Testani JM. Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure. The American Journal Of Cardiology 2019, 124: 1707-1711. PMID: 31601358, PMCID: PMC6959849, DOI: 10.1016/j.amjcard.2019.08.034.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureHeart failureImproved survivalHigher loop diuretic dosesLoop diuretic dosesNet fluid lossPlasma volume reductionAggressive decongestionAggressive diuresisPostdischarge survivalDiuretic dosesPostdischarge outcomesSerum creatinineHospital treatmentHospital parametersBetter survivalCreatinineHemoconcentrationPatient carePatientsSurvivalLonger lengthVolume reductionTreatmentRenal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function
Rao VS, Ahmad T, Brisco-Bacik MA, Bonventre JV, Wilson FP, Siew ED, Felker GM, Anstrom KK, Mahoney DD, Bart BA, Tang WHW, Velazquez EJ, Testani JM. Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. Circulation Heart Failure 2019, 12: e005552. PMID: 31163974, PMCID: PMC6585463, DOI: 10.1161/circheartfailure.118.005552.Peer-Reviewed Original ResearchConceptsRenal tubular injury biomarkersTubular injury biomarkersHeart failure patientsAcute decompensated heart failure patientsDecompensated heart failure patientsTubular injury markersInjury biomarkersFailure patientsRenal functionInjury markersAcute decompensated heart failureVolume removalCARRESS-HF trialRenal function recoveryDecompensated heart failureRenal tubular injuryRenal effectsSerum creatinineTubular injuryBiomarker substudyHeart failurePharmacological therapyClinical outcomesFunction recoveryHigh incidenceUrine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, Obeid W, Lin H, Kuperman M, Moeckel GW, Kashgarian M, Cantley LG, Parikh CR. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight 2019, 4: e127456. PMID: 31092735, PMCID: PMC6542610, DOI: 10.1172/jci.insight.127456.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney diseasePrebiopsy diagnosisKidney biopsyKidney diseaseIL-9AIN diagnosisUrine TNFInterstitial nephritisSpecific T cell subsetsAcute tubular injuryDiabetic kidney diseaseIL-9 levelsTNF-α levelsT cell subsetsAddition of biomarkersPlasma cytokinesCytokine levelsTubular injuryHighest quartileMultivariable analysisCell subsetsUrinary TNFBlood eosinophilsGlomerular diseaseElectronic Alerts for Acute Kidney Injury Amelioration (ELAIA-1): a completely electronic, multicentre, randomised controlled trial: design and rationale
Mutter M, Martin M, Yamamoto Y, Biswas A, Etropolski B, Feldman H, Garg A, Gourlie N, Latham S, Lin H, Palevsky PM, Parikh C, Moreira E, Ugwuowo U, Wilson FP. Electronic Alerts for Acute Kidney Injury Amelioration (ELAIA-1): a completely electronic, multicentre, randomised controlled trial: design and rationale. BMJ Open 2019, 9: e025117. PMID: 31154298, PMCID: PMC6549649, DOI: 10.1136/bmjopen-2018-025117.Peer-Reviewed Original ResearchConceptsAcute kidney injuryElectronic alertsMedical intensive care unitYale-New Haven HospitalDays of randomisationIntensive care unitElectronic alert systemNew Haven HospitalAppropriate ethics committeeElectronic medical record systemAKI alertsAKI progressionAlert specificityInpatient dialysisKidney injuryHospitalised patientsPeer-reviewed journalsUsual careInpatient deathMedical record systemPrimary outcomeCare unitExclusion criteriaOrder setsInformed consentThe Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery
Mansour SG, Zhang WR, Moledina D, Coca SG, Jia Y, Thiessen-Philbrook H, McArthur E, Inoue K, Koyner JL, Shlipak MG, Wilson FP, Garg AX, Ishibe S, Parikh CR, Consortium T. The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery. American Journal Of Kidney Diseases 2019, 74: 36-46. PMID: 30955944, PMCID: PMC6591032, DOI: 10.1053/j.ajkd.2019.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersCardiac Surgical ProceduresCreatinineEndpoint DeterminationFemaleHumansKidneyMaleMiddle AgedNeovascularization, PhysiologicOutcome Assessment, Health CarePostoperative ComplicationsProspective StudiesReceptors, Vascular Endothelial Growth FactorRisk AssessmentUnited StatesVascular Endothelial Growth Factor AConceptsAcute kidney injuryCardiac surgeryAKI durationKidney injuryProangiogenic markersAngiogenesis markersOutcomes of AKILong-term outcomesPlasma VEGF concentrationsTRIBE-AKI cohortAntiangiogenic markersCause mortalityPreoperative concentrationsHospital dischargeProcess of angiogenesisMarker levelsVEGFR1 levelsPGF concentrationsHigher oddsMortality riskHigh riskLower oddsVEGF concentrationsAngiogenic markersSurgery
2018
The Trifecta of Precision Care in Heart Failure Biology, Biomarkers, and Big Data ∗
Ahmad T, Wilson FP, Desai NR. The Trifecta of Precision Care in Heart Failure Biology, Biomarkers, and Big Data ∗. Journal Of The American College Of Cardiology 2018, 72: 1091-1094. PMID: 30165979, PMCID: PMC6345377, DOI: 10.1016/j.jacc.2018.07.009.Commentaries, Editorials and Letters